ArticleCancer communications (London, England)2019

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.

Wen Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.